With Qynapse we all benefit from earlier and more accurate monitoring of patients.
Patients, practitioners, researchers and you – the payer, all benefit from earlier, more accurate central nervous system disease diagnosis and monitoring of patients throughout the care continuum.
Qynapse has the potential to help lower costs, drive up quality outcomes and improve patient satisfaction. Are you ready to transform neuroscience with us?
Potential to revolutionize diagnosis, care and monitoring of CNS diseases to improve outcomes.
The Qynapse team is on the forefront of neuroimaging and the early prognosis on progress is astounding. Our neuroimaging tool, QyScore®, has been implemented in US and EU clinics and is expanding soon into new global markets and used in multi-site clinical trials and global research collaborations.
When leveraged in a clinical setting, QyScore® provides objective and reliable measures to potentially improve the accuracy of diagnosis, precisely evaluate therapeutic impact and reliably measure disease progression. This also creates the potential for patients to experience a shorter time to diagnosis, fewer clinical visits and a more personalized therapeutic intervention. If these ends are achieved, this may lead to better patient outcomes, improved quality of life, and decreased costs over the CNS care pathway.
Our technology is a game changer.
Our neuroimaging software platform, QyScore®:
- Provides precise, accurate, objective readouts that may decrease the likelihood of misdiagnosis, which may create transparency to more effectively and efficiently manage patient outcomes
- Creates the potential for better longitudinal monitoring of disease progression and therapeutic effectiveness, which may help to better manage costs and maximize outcomes
- Has demonstrated better performance when compared to certain other state-of-the-art automated methods on the market
Qynapse provides information to clinicians which may help address the misdiagnosis rate in CNS, which is upwards of 30%
Precise Diagnosis & Monitoring
Qynapse has the potential to help facilitate a more precise diagnosis and monitoring of disease progression
$1 Trillion by 2050
Amongst the most expensive diseases to manage, Alzheimer’s is expected to cost the US healthcare system over $1 trillion by 2050
Former CEO | UnitedHealthcare Specialty Benefits
Payers have developed very sophisticated systems and data sets to help their members, healthcare providers and teams make better decisions about healthcare. What Qynapse provides further enhances that decision making, resulting from the whole being greater than the sum of the parts.
Founder & CEO | Qynapse
When someone you love is declining mentally, there’s nothing worse than not having a clear diagnosis as to why. That’s why Qynapse is on a mission to transform time to diagnosis and the accuracy for diagnosis for CNS disease.
Srinivas Peddi, MD
Radiologist & Board Member | Tower Imaging Medical Group
When you remove air from a ball, it’s hard to figure that out until it’s lost a lot of volume. But if we had a tool that would let us measure more precisely? That’s super helpful. And that’s what Qynapse provides.
Bruno Dubois, MD, PhD
Professor of Neurology | Sorbonne University, Director of the Institute of Memory and Alzheimer’s Disease (IM2A) | Pitié Salpêtrière Hospital in Paris
In light of the recent breakthrough for Alzheimer’s patients – the approval of new treatment options by the FDA, Qynapse’s vision is becoming even more critical to advance the early detection of Alzheimer’s disease and to precisely monitor the therapy efficacy and safety.
David Merrill, MD, PhD
Director | Pacific Brain Health Center Pacific Neuroscience Institute
I’m excited to use QyScore® to quantify both volumetric and white matter integrity in our patients – bringing such an important layer of precision and objectivity to inform our clinical decisions.
Marwan N. Sabbagh
MD, FAAN, CCRI
Going from a diagnostic accuracy of 66-70% to better than 90% is today the most pressing topic for the Alzheimer’s disease community. I am glad to see innovative organizations like Qynapse leading the way and contributing to transform the diagnosis of Alzheimer’s disease.
Bring Qynapse to
Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI).
Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.